FDA’s June 2026 guide directs sponsors to the IS domain for collected immunogenicity data and for immunogenicity titer results.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
FDA’s June 2026 technical guide says the Immunogenicity (IS) domain should be submitted for individual studies in which immunogenicity data are collected, and titer results belong in IS rather than a supplemental qualifier dataset.
Key details
Core IssueFDA’s June 2026 guide directs sponsors to the IS domain for collected immunogenicity data and for immunogenicity titer results.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
This is current FDA technical-conformance guidance for electronic study-data submissions; recheck the current FDA guide, supported standards, Data Standards Catalog, and eCTD specifications before relying on version-sensitive requirements.
Further guidance
Content
Submit immunogenicity observations in the IS domain when the study collected them; place titer results in IS rather than moving them into supplemental qualifiers.
Purpose
Keep immunogenicity data in the expected standard domain so reviewers can find and interpret it consistently.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
FDA’s June 2026 guide says the AE domain should include all adverse events unless an indication-specific technical specification says otherwise and asks for the criterion supporting a serious-event flag.
FDA’s June 2026 guide describes the DD (Death Details) domain for supplemental information collected when a death occurs and expects consistency with relevant AE-domain death variables.
FDA’s June 2026 conformance guide says screen failures, when provided, should be represented as a DM record with specified planned/actual arm fields left blank.
FDA’s June 2026 guide gives DS-domain handling for multiple disposition events, including use of EPOCH or DSSCAT and a specific final-record convention for death.
FDA’s June 2026 guide explicitly calls for the DV domain in submissions containing protocol-deviation data and identifies review-oriented variables beyond CDISC-required fields.
FDA’s June 2026 guide gives a direct placement rule for viral-load results in standardized clinical study data: place them in the MB (Microbiology) domain.
